DNases, Ligases, and RNA Polymerases Market

Global DNases, Ligases, and RNA Polymerases Market Size, Share & Trends Analysis Report By DNases Application, By Ligases Application (Oligonucleotide Synthesis and Others), By RNA Polymerases Application, By Regional Outlook and Forecast, 2024 - 2031

Report Id: KBV-23134 Publication Date: June-2024 Number of Pages: 215
2023
USD 740.9 Million
2031
USD 1.6 Billion
CAGR
10.4%
Historical Data
2020 to 2022

Market Report Description

The Global DNases, Ligases, And RNA Polymerases Market size is expected to reach $1.6 billion by 2031, rising at a market growth of 10.4% CAGR during the forecast period.

North America is home to some of the world’s leading biotechnology and pharmaceutical companies, particularly the United States. Thus, the North America region acquired $273.68 million revenue in 2023. Increased use of DNases, Ligases, And RNA Polymerases results from this financial support. These enzymes are necessary for various molecular biology and genetic engineering applications. Specific grants and subsidies targeted at innovative pharmaceutical research bolster the demand for these enzymes as they are critical tools in developing new drugs and therapies.

DNases, Ligases, and RNA Polymerases Market Size - Global Opportunities and Trends Analysis Report 2020-2031

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In 2022, February, QIAGEN formed a partnership with Singular Genomics Systems to verify its QIAseq kits, a product line for both RNA and DNA sample prep, with the G4 analysis platform. Additionally, In 2021, August, QIAGEN came into a partnership with GT Molecular to deliver a comprehensive wastewater workflow solution developed to allow management of COVID-19 outbreaks by U.S. and Canadian laboratories, with forthcoming opportunities to deliver the solution in other countries.

KBV Cardinal Matrix - Market Competition Analysis

Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific, Inc. is the forerunner in the DNases, Ligases, And RNA Polymerases Market. In February 2022, Thermo Fisher Scientific joined hands with Moderna, a biotechnology company developing messenger RNA. Under this collaboration, the companies aimed to allow reliable large-scale manufacturing in the U.S. of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA drugs in its channel. Companies such as Merck KGaA, Agilent Technologies, Inc., Qiagen N.V are some of the key innovators in DNases, Ligases, And RNA Polymerases Market.

DNases, Ligases, and RNA Polymerases Market - Competitive Landscape and Trends by Forecast 2031

COVID-19 Impact Analysis

In the early stages of the pandemic, disruptions to global supply chains, logistics, and manufacturing operations affected the availability of DNases, Ligases, RNA Polymerases, and other molecular biology reagents. Border closures, travel restrictions, and lockdown measures impeded the movement of goods, leading to product shipment and distribution delays. The COVID-19 pandemic disrupted research and development activities in academic institutions, biotechnology companies, and pharmaceutical firms, affecting experimental timelines and project progress. Thus, the Impact of the COVID-19 pandemic had a moderate impact on the market.

Market Growth Factors

Genomic research involves the study of DNA and RNA sequences to understand genetic variations, gene expression patterns, and molecular mechanisms underlying biological processes. DNases, Ligases, And RNA Polymerases are essential enzymes used in nucleic acid manipulation techniques such as sequencing, PCR amplification, cloning, and gene expression analysis, driving market demand. Hence, the expansion of genomic research is driving the market’s growth.

The biotechnology and pharmaceutical industries rely heavily on DNases, Ligases, And RNA Polymerases for various applications in biopharmaceutical development. These enzymes are essential for molecular cloning, gene expression, protein production, and recombinant DNA technology used in biologics production, such as therapeutic proteins, monoclonal antibodies, and gene therapies. Thus, the biotechnology and pharmaceutical industries are propelling the market’s growth.

Market Restraining Factors

Enzyme production involves complex manufacturing processes, including fermentation, purification, and formulation, which require specialized equipment, facilities, and expertise. These processes are resource-intensive and require substantial investments in infrastructure, technology, and skilled personnel, contributing to high production costs. Therefore, the high enzyme production costs are propelling the market’s growth.

Driving and Restraining Factors
DNases, Ligases, and RNA Polymerases Market
  • Expansion of genomic research
  • Growth in the biotechnology and pharmaceutical industries
  • Prevalence of genetic disorders and infectious diseases
  • High costs of enzyme production
  • Limited shelf life and stability
  • Increasing demand for molecular diagnostics
  • Increasing investment in precision agriculture
  • Shortage of skilled professionals
  • Increasing competition from alternative technologies

DNases Application Outlook

Based on DNases application, the market is divided into biopharmaceutical processing and others. The others segment witnessed a 23% revenue share in the market in 2023. DNases are utilized in environmental biotechnology to degrade DNA contaminants in soil and water, aiding in the bioremediation of polluted environments. DNases are also used in the food industry to remove DNA from food products, such as dairy and meat, to prevent spoilage and improve shelf life.

Ligases Application Outlook

On the basis of Ligases application, the market is segmented into oligonucleotide synthesis and other. In 2023, the other segments attained a 56% revenue share in the market. Ligases join DNA fragments, such as vectors, during molecular cloning and subcloning procedures and insert DNA. They facilitate the assembly of synthetic genes by ligating oligonucleotide fragments into longer DNA sequences.

DNases, Ligases, and RNA Polymerases Market Share and Industry Analysis Report 2023

RNA Polymerases Application Outlook

By RNA polymerases application, the market is divided into mRNA production and others. The others segment procured a remarkable revenue share in the market in 2023. RNA polymerases are utilized in IVT reactions to produce RNA transcripts from DNA templates in vitro. These synthetic RNA molecules serve as valuable tools in molecular biology research, enabling the generation of RNA probes, standards, controls, and expression vectors for various applications.

Free Valuable Insights: Global DNases, Ligases, and RNA Polymerases Market size to reach USD 1.6 Billion by 2031

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2023, the Asia Pacific region generated a substantial 28% revenue share in the market. The Asia Pacific region is home to large-scale genomic research initiatives to understand genetic variations, disease mechanisms, and population genetics. DNases, Ligases, And RNA Polymerases play crucial roles in genomic research, including DNA sequencing, gene expression analysis, and genome editing, driving demand for enzyme products in academic and research institutions across the region.

DNases, Ligases, and RNA Polymerases Market Report Coverage
Report Attribute Details
Market size value in 2023 USD 740.9 Million
Market size forecast in 2031 USD 1.6 Billion
Base Year 2023
Historical Period 2020 to 2022
Forecast Period 2024 to 2031
Revenue Growth Rate CAGR of 10.4% from 2024 to 2031
Number of Pages 215
Number of Tables 324
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments covered DNases Application, Ligases Application, RNA Polymerases Application, Region
Country scope
  • North America (US, Canada, Mexico, and Rest of North America)
  • Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific)
  • LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies Included Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., Promega Corporation, Raybiotech Life, Inc., Qiagen N.V, Abnova Corporation, Takara Bio Inc. (Takara Holdings Inc.), BPS Bioscience, Inc., New England Biolabs, Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

Recent Strategies Deployed in the Market

  • Jan-2023: Agilent Technologies Inc. took over Avida Biomed, an early-stage life sciences company developing high-performance target enrichment workflows with unique capabilities. This acquisition would complement company’s market-leading SureSelect portfolio and further augment Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets.
  • Feb-2022: Thermo Fisher Scientific joined hands with Moderna, a biotechnology company developing messenger RNA. Under this collaboration, the companies aimed to allow reliable large-scale manufacturing in the U.S. of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA drugs in its channel.
  • Feb-2022: Merck KGaA came into a partnership with eTheRNA, a science and technology organization. Together the companies would target messenger RNA therapeutics using eTheRNA’s mRNA and lipid nanoparticle technologies in multiple model methods. Additionally, mRNA encoding antigens would be selected by Merck KGaA as suitable for human diseases. Moreover, eTheRNA acquires immunotherapies that target the essential role of dendritic cells in the human immune system.
  • Feb-2022: Merck completed the acquisition of Exelead, a biopharmaceutical contract development, and manufacturing business. Through this acquisition, Exelead’s leading abilities, and highly experienced crew, Merck acquires a crucial landmark in evolving one of the supreme CDMO players in mRNA vaccines and therapeutics, delivering a combined CDMO across the mRNA value chain from pre-clinical to retail.
  • Feb-2022: QIAGEN formed a partnership with Singular Genomics Systems, a company leveraging novel next-generation sequencing. With this partnership, QIAGEN aimed to verify its QIAseq kits, a product line for both RNA and DNA sample prep, with the G4 analysis platform. Additionally, this partnership would highlight QIAGEN's dedication to delivering a plug-and-play solution for consumers to combine the G4 into living NGS workflows.

List of Key Companies Profiled

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Promega Corporation
  • Raybiotech Life, Inc.
  • Qiagen N.V
  • Abnova Corporation
  • Takara Bio Inc. (Takara Holdings Inc.)
  • BPS Bioscience, Inc.
  • New England Biolabs, Inc.

DNases, Ligases, and RNA Polymerases Market Report Segmentation

By DNases Application

  • Biopharmaceutical Processing
  • Others

By Ligases Application

  • Oligonucleotide Synthesis
  • Others

By RNA Polymerases Application

  • mRNA Production
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Frequently Asked Questions About This Report

This Market size is expected to reach $1.6 billion by 2031.

Expansion of genomic research are driving the Market in coming years, however, High costs of enzyme production restraints the growth of the Market.

Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., Promega Corporation, Raybiotech Life, Inc., Qiagen N.V, Abnova Corporation, Takara Bio Inc. (Takara Holdings Inc.), BPS Bioscience, Inc., New England Biolabs, Inc.

The expected CAGR of this Market is 10.4% from 2023 to 2031.

The Oligonucleotide Synthesis segment is leading the Market by Ligases Application in 2023; thereby, achieving a market value of $725.1 Million by 2031.

The North America region dominated the Market by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $571.5 Million by 2031.

HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo